Initial Treatment of Severe Hemodynamically Stable Pulmonary Embolism

Risk Stratification

The European Society of Cardiology recommends that hemodynamic stability, not radiological severity, is the determining factor for management, with patients classified as intermediate or low risk if they are hemodynamically stable (blood pressure ≥90 mmHg, no shock) 1, 2
The American College of Chest Physicians suggests that additional stratification requires evaluation of right ventricular dysfunction (echocardiography) and myocardial injury biomarkers to determine intermediate-high vs intermediate-low risk 5

The European Heart Journal recommends that direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists as first-line treatment, with apixaban or rivaroxaban as initial options 1, 2
The dosing for apixaban is 10 mg every 12 hours for 7 days, then 5 mg every 12 hours 5
The dosing for rivaroxaban is 15 mg every 12 hours for 21 days, then 20 mg once daily 4

The European Society of Cardiology states that DOACs are contraindicated in severe renal insufficiency (creatinine clearance <30 ml/min), antiphospholipid syndrome, pregnancy, or lactation 1, 2, 3, 4

The European Heart Journal recommends that systemic thrombolysis is not routinely recommended for intermediate or low-risk pulmonary embolism, and is reserved for high-risk patients with hemodynamic instability (blood pressure <90 mmHg or shock) 1, 2, 5

The American College of Chest Physicians suggests that anticoagulant therapy should be continued for at least 3 months, with extension of treatment based on individual risk-benefit assessment 6, 1, 2
For provoked pulmonary embolism with a transient major risk factor, anticoagulation can be stopped after 3 months, while unprovoked or persistent risk factor-associated pulmonary embolism may require indefinite anticoagulation 1, 2, 4